NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

Contract summary

Industry

• Pharmaceutical products - 33600000

Location of contract

East Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber

Value of contract

£2,028,332,000

Procurement reference

CF-2825700D0O000000rwimUAA

Published date

17 February 2025

Closing date

7 April 2025

Closing time

1pm

Contract start date

1 September 2025

Contract end date

31 August 2027

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

---

Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

Offer reference number: CM/PHR/24/5680

CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027

CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

---

More information

Attachments

• Document No. 05c - Volume Discounts or Additional Products Offer Schedule - CM-PHR-24-5680.xls
• Document No. 05c - Volume Discounts or Additional Products Offer Schedule - CM-PHR-24-5680

• Document No. 09 - Tender Design and Instructions on Completing the Offer Schedule.doc
• Document No. 09 - Tender Design and Instructions on Completing the Offer Schedule

• Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements.docx
• Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements

• Document No. 07a - Quality Control Technical Sheet.doc
• Document No. 07a - Quality Control Technical Sheet

• Document No. 07b - Quality Assurance Policy to Support the National Contract Procurement of Licensed Medicines v6 (Issued October 2023).docx
• Document No. 07b - Quality Assurance Policy to Support the National Contract Procurement of Licensed Medicines v6 (Issued October 2023)

• Document No. 08 - Confidential Information Schedule - CM_PHR_24_5680.xls
• Document No. 08 - Confidential Information Schedule - CM_PHR_24_5680

• Document No. 05 - Selectt Offer Schedule Instructions - CM-PHR-24-5680.docx
• Document No. 05 - Selectt Offer Schedule Instructions - CM-PHR-24-5680

• Document No. 06 - Form of Offer - CM_PHR_24_5680.doc
• Document No. 06 - Form of Offer - CM_PHR_24_5680

• Document No. 05a(ii) - Selectt Offer Schedule - CM_PHR_24_5680_02.xml
• Document No. 05a(ii) - Selectt Offer Schedule - CM_PHR_24_5680_02

• Document No. 10 - Participating Authorities - CM_PHR_24_5680.xls
• Document No. 10 - Participating Authorities - CM_PHR_24_5680

• Document No. 02 - Terms of offer.docx
• Document No. 02 - Terms of offer

• Document No. 04a - Quality Assurance Process.doc
• Document No. 04a - Quality Assurance Process

• Document No. 05a(i) - Selectt Offer Schedule - CM_PHR_24_5680_01.xml
• Document No. 05a(i) - Selectt Offer Schedule - CM_PHR_24_5680_01

• Document No. 05b(i) - Tender Product Listing and Usage - CM_PHR_24_5680_01.xlsx
• Document No. 05b(i) - Tender Product Listing and Usage - CM_PHR_24_5680_01

• Document No. 03 - Framework Agreement and Terms and Conditions - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab - 1 September 2025.docx
• Document No. 03 - Framework Agreement and Terms and Conditions - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab - 1 September 2025

• Document No. 01 - Invitation to offer covering letter.docx
• Document No. 01 - Invitation to offer covering letter

• Document No. 05b(ii)- Tender Product Listing and Usage - CM_PHR_24_5680_02.xlsx
• Document No. 05b(ii)- Tender Product Listing and Usage - CM_PHR_24_5680_02

Additional text

To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.

Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:

Phone: 0800 9956035

E-mail: support-health@atamis.co.uk

---

About the buyer

Contact name

Lynne Tierney

Address

2nd Floor Rutland House
Runcorn
WA7 2ES
GB

Email

lynne.tierney@nhs.net